Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...

Developed under an exclusive worldwide licence agreement with UCB, PTD802 is designed to counteract the effects of ...

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...

Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802.

New research findings dispel the dogma that slower hyponatremia correction is better. Faster correction of severe hyponatremia is associated with a lower death rate, investigators report.

neuro.med.kyushu-u.ac.jp Objectives To clarify the clinical features of combined central and peripheral demyelination (CCPD) via a nationwide survey. Methods The following characteristics were used to ...

An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in ...

Generally, inflammatory demyelinating diseases selectively affect either the central or peripheral myelin. Here we report a case of a severe combined central and peripheral demyelination, each of ...

The following is a summary of “Enhancing the effect of rehabilitation on Multiple Sclerosis: A Randomized Clinical Trial ...

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to ...